- Home
- CANF vs ELSE Comparison
CANF vs ELSE Comparison
Compare CANF & ELSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- ELSE
- Stock Information
- Founded
- CANF 1994
- ELSE 1968
- Country
- CANF Israel
- ELSE United States
- Employees
- CANF N/A
- ELSE N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- ELSE Industrial Machinery/Components
- Sector
- CANF Health Care
- ELSE Industrials
- Exchange
- CANF Nasdaq
- ELSE Nasdaq
- Market Cap
- CANF 14.4M
- ELSE 15.8M
- IPO Year
- CANF N/A
- ELSE N/A
- Fundamental
- Price
- CANF $1.48
- ELSE $5.30
- Analyst Decision
- CANF Strong Buy
- ELSE
- Analyst Count
- CANF 2
- ELSE 0
- Target Price
- CANF $14.00
- ELSE N/A
- AVG Volume (30 Days)
- CANF 1.2M
- ELSE 5.8K
- Earning Date
- CANF 12-31-2024
- ELSE 11-13-2024
- Dividend Yield
- CANF N/A
- ELSE N/A
- EPS Growth
- CANF N/A
- ELSE 29.91
- EPS
- CANF N/A
- ELSE 0.13
- Revenue
- CANF $667,000.00
- ELSE $9,289,000.00
- Revenue This Year
- CANF $409.56
- ELSE N/A
- Revenue Next Year
- CANF N/A
- ELSE N/A
- P/E Ratio
- CANF N/A
- ELSE $41.29
- Revenue Growth
- CANF N/A
- ELSE 11.21
- 52 Week Low
- CANF $1.29
- ELSE $3.74
- 52 Week High
- CANF $4.69
- ELSE $5.37
- Technical
- Relative Strength Index (RSI)
- CANF 35.58
- ELSE 80.29
- Support Level
- CANF $1.30
- ELSE $4.31
- Resistance Level
- CANF $1.72
- ELSE $5.37
- Average True Range (ATR)
- CANF 0.18
- ELSE 0.15
- MACD
- CANF -0.01
- ELSE 0.08
- Stochastic Oscillator
- CANF 17.92
- ELSE 93.40
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About ELSE Electro-Sensors Inc.
Electro-Sensors Inc is engaged in manufacturing and selling a variety of monitoring systems that measure actual machine production and operation rates, as well as systems that regulate the speed of related machines in production processes. Its speed monitoring systems compare revolutions per minute or speed against acceptable rates as determined by a customer. It also includes a line of products that measure production counts or rates, such as parts, gallons, or board feet, alarm systems, tachometers, and other devices that translate impulses from the sensors into alarm signals, computer inputs, or digital displays that are usable by the customer.